{"record":{"code":"W-01638","indicator":"Debarred / sanctioned abroad × US SEC issuer","class_b":false,"subject":"NVS · SUB · EC · HOSPITAL HOMERO CASTANIER CRESPO","buyer":"","amount":13041.6,"currency":null,"records":2,"found":"2026-10-04","refs":["SICM2-628-2016","ocds-5wno2w-CE-20250002786283-8380","ocds-5wno2w-CE-20250002902036-8380","2020-06-25","2016-03-23"],"id":"W-01638","html":"https://worldwide-corruption.com/record/ecuador/findings/fcpa-pattern/W-01638/","json":"https://worldwide-corruption.com/record/ecuador/findings/fcpa-pattern/W-01638/index.json","why":"Indicator “Debarred / sanctioned abroad × US SEC issuer”: subsidiary/issuer «NOVARTIS ECUADOR S.A.» ↔ SEC NVS (CIK 1114448, NOVARTIS AG): 2 non-competitive contracts at the buyer «HOSPITAL HOMERO CASTANIER CRESPO», 13,042 USD (≈ $13,042); method direct (Catálogo electrónico - Compra directa en el convenio SICM2-628-2016, ADQUISICION DE CATALOGO DE MEDICAMENTOS, SELECCION DE PROVEEDORES PARA LA PROVISIÓN DE MEDICAMENTOS DE USO Y CONSUMO; OCID ocds-5wno2w-CE-20250002786283-8380, ocds-5wno2w-CE-20250002902036-8380; ⚑ REPEAT: already sanctioned SEC by FCPA (2020-06-25 Novartis AG, 2016-03-23 Novartis AG); ↓ weak method (catalogue / exclusivity / accreditation / small purchase).","facts":[["Company / subject","NVS · SUB · EC · HOSPITAL HOMERO CASTANIER CRESPO",null],["Indicator","Debarred / sanctioned abroad × US SEC issuer",null],["Amount","13,042",null],["Records behind the indicator","2",null],["Found","4 October 2026",null],["Code","W-01638",null],["Reference","SICM2-628-2016",null],["Reference","ocds-5wno2w-CE-20250002786283-8380",null],["Reference","ocds-5wno2w-CE-20250002902036-8380",null],["Reference","2020-06-25",null],["Reference","2016-03-23",null]],"summary":"subsidiary/issuer «NOVARTIS ECUADOR S.A.» ↔ SEC NVS (CIK 1114448, NOVARTIS AG): 2 non-competitive contracts at the buyer «HOSPITAL HOMERO CASTANIER CRESPO», 13,042 USD (≈ $13,042); method direct (Catálogo electrónico - Compra directa en el convenio SICM2-628-2016, ADQUISICION DE CATALOGO DE MEDICAMENTOS, SELECCION DE PROVEEDORES PARA LA PROVISIÓN DE MEDICAMENTOS DE USO Y CONSUMO; OCID ocds-5wno2w-CE-20250002786283-8380, ocds-5wno2w-CE-20250002902036-8380; ⚑ REPEAT: already sanctioned SEC by FCPA (2020-06-25 Novartis AG, 2016-03-23 Novartis AG); ↓ weak method (catalogue / exclusivity / accreditation / small purchase)","entity":"2fe10920"},"about":"Indicators computed from public data sets: contracts, payments, registers, trade and sanctions lists. An indicator is a reason to check, not a decision of a public authority.","evidence":[],"row":{"country":"Ecuador","iso2":"EC","part":"Findings","indicator":"Debarred / sanctioned abroad × US SEC issuer","about":"Indicators computed from public data sets: contracts, payments, registers, trade and sanctions lists. An indicator is a reason to check, not a decision of a public authority.","findings":84,"new_today":0,"on_pages":84,"full_list":[],"html":"https://worldwide-corruption.com/database/ecuador/findings/fcpa-pattern/","json":"https://worldwide-corruption.com/database/ecuador/findings/fcpa-pattern/index.json"},"other_records_of_this_company":[],"html":"https://worldwide-corruption.com/record/ecuador/findings/fcpa-pattern/W-01638/","json":"https://worldwide-corruption.com/record/ecuador/findings/fcpa-pattern/W-01638/index.json"}